Unknown

Dataset Information

0

The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells.


ABSTRACT: Cancer immunotherapy using chimeric antigen receptor-armed T (CAR T) cells have been shown to improve outcomes significantly in patients with hematological malignancies. However, cytokine release syndrome (CRS) remains a risk. CRS is characterized by the excessive activation of CAR T cells and macrophages. Signs and symptoms of CRS are usually resolved after steroid administration, but steroids abrogate the expansion and persistence of CAR T cell populations. Tocilizumab is a humanized monoclonal antibody (mAb) that attenuates CRS without significant loss of CAR T cell activity. However, interleukin-6 (IL-6)/IL-6 receptor (IL-6R) blockade alone cannot relieve CRS symptoms fully, and novel treatments are needed to prevent or cure CRS. TO-207 is an N-benzoyl-L-phenylalanine derivative that significantly inhibits inflammatory cytokine production in human monocyte and macrophage-specific manner. We investigated whether TO-207 could inhibit cytokine production without impairing CAR T cell function in a CRS-simulating co-culture system.

SUBMITTER: Futami M 

PROVIDER: S-EPMC7176125 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells.

Futami Muneyoshi M   Suzuki Keisuke K   Kato Satomi S   Ohmae Saori S   Tahara Yoshio Y   Nojima Masanori M   Imai Yoichi Y   Mimura Takayuki T   Watanabe Yoshihiro Y   Tojo Arinobu A  

PloS one 20200422 4


Cancer immunotherapy using chimeric antigen receptor-armed T (CAR T) cells have been shown to improve outcomes significantly in patients with hematological malignancies. However, cytokine release syndrome (CRS) remains a risk. CRS is characterized by the excessive activation of CAR T cells and macrophages. Signs and symptoms of CRS are usually resolved after steroid administration, but steroids abrogate the expansion and persistence of CAR T cell populations. Tocilizumab is a humanized monoclona  ...[more]

Similar Datasets

| S-EPMC8793151 | biostudies-literature
| S-EPMC5316963 | biostudies-literature
| S-EPMC11319489 | biostudies-literature
| S-BSST1437 | biostudies-other
| S-SCDT-10_1038-S44321-024-00093-3 | biostudies-other
| S-EPMC3290426 | biostudies-literature
| S-EPMC523259 | biostudies-other
| S-EPMC10455244 | biostudies-literature
| S-EPMC5712342 | biostudies-literature
| S-EPMC8340038 | biostudies-literature